Pfizer Inc (PFE)

$24.67 +0.13 (0.53%)
Market Cap 139.86B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.17
Forward PE 8.46
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 38,355,100
Avg Vol 41,473,383
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 27%
Beta 0.35
Analysts Sell
Price Target $28.70

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Micheal_Pothead
Micheal_Pothead Jul. 28 at 3:06 PM
$PFE it’s trying to do the thing..
0 · Reply
JBS_84
JBS_84 Jul. 28 at 2:59 PM
$PFE 25.5 is the 20 week ema. The 50 week ema and convergence of 200 day sit around 25.75.
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 28 at 2:51 PM
$PFE 25.50 on the dot twice today lol
0 · Reply
Willieberich
Willieberich Jul. 28 at 2:34 PM
$PFE still here .looking for 28 .will get there in time.
0 · Reply
Yonia
Yonia Jul. 28 at 2:03 PM
$PFE look at $T $VZ $BRK.B $WMT , that’s what being inverse of the market looks like
0 · Reply
Yonia
Yonia Jul. 28 at 2:02 PM
$PFE 🤣🤣🤣🤣🤣🤣
0 · Reply
nimii
nimii Jul. 28 at 1:56 PM
$PFE 😡😤
0 · Reply
ProTraderColin
ProTraderColin Jul. 28 at 1:52 PM
$PFE nice push
0 · Reply
Gj64
Gj64 Jul. 28 at 1:52 PM
$PFE https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3688878:0-pfizer-q1-fy27-saw-higher-revenue-and-profit-with-eps-up-and-strong-equity-despite-exceptional-costs/
0 · Reply
BullMaven
BullMaven Jul. 28 at 1:51 PM
$PFE nice green candle
0 · Reply
Latest News on PFE
Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:48 PM EDT - 5 days ago

Pfizer's prostate cancer drug combination gets US FDA priority review

FDA grants priority review for Pfizer’s Talzena plus Xtandi

2026-07-22T20:40:37.000Z - 5 days ago

FDA grants priority review for Pfizer’s Talzena plus Xtandi

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 22, 2026, 4:30 PM EDT - 5 days ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

Jul 21, 2026, 7:10 PM EDT - 6 days ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 16, 2026, 1:39 PM EDT - 11 days ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Arbutus initiates patent infringement actions against Pfizer, BioNTech

2026-07-16T11:45:21.000Z - 12 days ago

Arbutus initiates patent infringement actions against Pfizer, BioNTech

ABUS BNTX ROIV

Pfizer price target lowered to $30 from $34 at BMO Capital

2026-07-13T12:26:33.000Z - 15 days ago

Pfizer price target lowered to $30 from $34 at BMO Capital

Pfizer price target lowered to $35 from $36 at Guggenheim

2026-07-13T11:06:16.000Z - 15 days ago

Pfizer price target lowered to $35 from $36 at Guggenheim

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

2026-07-10T15:30:20.000Z - 18 days ago

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

MRK

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 10, 2026, 11:23 AM EDT - 18 days ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer price target lowered to $26 from $27 at BofA

2026-07-10T10:30:21.000Z - 18 days ago

Pfizer price target lowered to $26 from $27 at BofA

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

2026-07-09T18:30:15.000Z - 18 days ago

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

AZN

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 22 days ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 4 weeks ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 29, 2026, 1:20 AM EDT - 4 weeks ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 4 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 4 weeks ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 4 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 4 weeks ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 5 weeks ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 5 weeks ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 5 weeks ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 5 weeks ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 5 weeks ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 6 weeks ago

Pfizer CEO warns German investment at risk over drug pricing policies

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 6 weeks ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 7 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 7 weeks ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 7 weeks ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 7 weeks ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 7 weeks ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 7 weeks ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 7 weeks ago

Pfizer Slides: Study update

Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 7 weeks ago

Pfizer Press release: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 7 weeks ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 7 weeks ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 7 weeks ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 7 weeks ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 7 weeks ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 2 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 2 months ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 2 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026, 8:00 AM EDT - 2 months ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 11:10 PM EDT - 2 months ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:19 PM EDT - 2 months ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 2 months ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 2 months ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 9:00 AM EDT - 2 months ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:08 AM EDT - 2 months ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026, 5:05 AM EDT - 2 months ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 18, 2026, 8:00 AM EDT - 2 months ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

May 14, 2026, 2:22 PM EDT - 2 months ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 13, 2026, 6:45 AM EDT - 2 months ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

May 12, 2026, 8:00 AM EDT - 2 months ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026, 7:00 AM EDT - 2 months ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 2 months ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 2 months ago

Pfizer CEO on AI-designed molecule, and race to use new tech

3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 3 months ago

3 Dividend Stocks for May 2026

SYY WSO

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 3 months ago

Pfizer Earnings Call Transcript: Q1 2026

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 3 months ago

Pfizer Earnings release: Q1 2026

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 3 months ago

Pfizer Quarterly report: Q1 2026

Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 3 months ago

Pfizer Slides: Q1 2026

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 3 months ago

Pfizer Posts Better-Than-Expected Revenue, Profit

Micheal_Pothead
Micheal_Pothead Jul. 28 at 3:06 PM
$PFE it’s trying to do the thing..
0 · Reply
JBS_84
JBS_84 Jul. 28 at 2:59 PM
$PFE 25.5 is the 20 week ema. The 50 week ema and convergence of 200 day sit around 25.75.
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 28 at 2:51 PM
$PFE 25.50 on the dot twice today lol
0 · Reply
Willieberich
Willieberich Jul. 28 at 2:34 PM
$PFE still here .looking for 28 .will get there in time.
0 · Reply
Yonia
Yonia Jul. 28 at 2:03 PM
$PFE look at $T $VZ $BRK.B $WMT , that’s what being inverse of the market looks like
0 · Reply
Yonia
Yonia Jul. 28 at 2:02 PM
$PFE 🤣🤣🤣🤣🤣🤣
0 · Reply
nimii
nimii Jul. 28 at 1:56 PM
$PFE 😡😤
0 · Reply
ProTraderColin
ProTraderColin Jul. 28 at 1:52 PM
$PFE nice push
0 · Reply
Gj64
Gj64 Jul. 28 at 1:52 PM
$PFE https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3688878:0-pfizer-q1-fy27-saw-higher-revenue-and-profit-with-eps-up-and-strong-equity-despite-exceptional-costs/
0 · Reply
BullMaven
BullMaven Jul. 28 at 1:51 PM
$PFE nice green candle
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jul. 28 at 1:50 PM
$PFE - What the helly? Why is pharma mooning, in general? My $AZN, $GILD and $BMY are quite green as well. WHAT. THE. HELLY.
2 · Reply
Yonia
Yonia Jul. 28 at 1:43 PM
$PFE I’m glad I’m in calls, but pls hold gains & give us more
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 28 at 1:41 PM
$PFE tf?
2 · Reply
NorthOfSouth
NorthOfSouth Jul. 28 at 1:40 PM
$PFE 💩
0 · Reply
INEEDMONEY87
INEEDMONEY87 Jul. 28 at 1:11 PM
$PFE .20 cents to start the day....somethings off going down a dollar....
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 28 at 12:10 PM
$JNJ $LLY $PFE $MRNA Is today the Day? Elite Pharma ( ELTP ) Who is making a Deal?????
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 28 at 8:17 AM
$IGC 9 out of 10 patients improved in a new THC/CBD dementia study. The Alzheimer’s treatment landscape is changing—and IGC is in the game. 🚀 $PFE $MRNA
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 28 at 8:13 AM
$IGC The Real "5 Billion Dollar Question" The real multibillion-dollar question isn't whether melatonin allows for less THC than pure cannabis—it’s whether IGC-AD1 can reliably deliver clinically meaningful agitation relief without an FDA Black Box Warning. If the upcoming Phase 2 data confirms that this combination outperforms placebo while maintaining its clean safety profile, IGC will have validated a non-antipsychotic, non-antidepressant solution in a market desperate for safe alternatives. That statistical separation from placebo is the actual catalyst that unlocks the drug's full commercial value. $PFE $MRNA
0 · Reply
jerry9269
jerry9269 Jul. 27 at 8:03 PM
$ABBV $MRK $PFE $SLS
1 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 27 at 8:01 PM
$PFE lol… Pathetic
1 · Reply
Mike22332233
Mike22332233 Jul. 27 at 8:01 PM
$SLS NEW ACTION ALERT .... Just HOLD UNTIL BO of SLS ... ANY DAY COULD BE THE START OF IT !!!!! …. * 80th event = $18-$22 (Unless CEO stats at 80th that ALL the 46 patients still living are GPS, and then SLS goes into the $70's) * Trial Readout = $55-$75 * First BO Offer = $140-$160 * Final Bidding War BO = $202 * 2 or more of these BP will bid: $MRK, $ABBV, $PFE, BMY, LLY , RHHBY, NVS, AZN * BO winner will be MRK or RHHBY LIKE if you agree with my price targets ..... FOLLOW me 👉 @Mike22332233 to get complete SLS info
2 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 27 at 7:19 PM
$PFE three times*
0 · Reply